Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.

Rivero A, Rapado I, Tomás JF, Montalbán C, de Oña R, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, de Sevilla AF, de la Serna J, Martínez-López J.

Leuk Res. 2011 Apr;35(4):431-7. doi: 10.1016/j.leukres.2010.09.026. Epub 2010 Oct 27.

PMID:
21030078
2.

Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.

Jordheim LP.

Leuk Res. 2011 Apr;35(4):429-30. doi: 10.1016/j.leukres.2010.10.012. Epub 2010 Nov 4. No abstract available.

PMID:
21051086
3.

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.

Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M; Italian Lymphoma Study Group.

Cancer. 2007 Jul 1;110(1):121-8.

4.

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients.

Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, Huang W, Chen Z, Chen SJ.

Pharmacogenetics. 2004 Nov;14(11):759-68.

PMID:
15564883
5.

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F.

Semin Oncol. 2000 Dec;27(6 Suppl 12):37-41.

PMID:
11225999
6.

Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, Tomás JF.

Leuk Lymphoma. 2009 Aug;50(8):1283-9. doi: 10.1080/10428190903040006.

PMID:
19557622
8.

[Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].

Oborilová A, Mayer J, Korístek Z, Hofmanová Z, Vásová I, Navrátil M, Vinklárková J, Muzikárová M, Klabusay M, Matuska M.

Cas Lek Cesk. 2004;143(10):685-90. Czech.

PMID:
15584619
9.

Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.

Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, Glubrecht D, Jewell LD, Lai R, Lang T, Hanson J, Young JD, Merle-Béral H, Binet JL, Cass CE, Dumontet C.

Blood. 2005 Jan 15;105(2):767-74. Epub 2004 Sep 28.

10.

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.

Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH.

J Clin Oncol. 2005 Feb 1;23(4):694-704.

PMID:
15681517
11.

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF.

Cancer. 2004 May 15;100(10):2181-9. Review.

12.

Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.

Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, Piccirillo N, Chiusolo P, Sorà F, Innocenti I, Sica S, Leone G.

Ann Hematol. 2008 Nov;87(11):891-8. doi: 10.1007/s00277-008-0527-3. Epub 2008 Jun 28.

PMID:
18587576
13.
14.

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.

Luminari S, Marcheselli L, Sacchi S, Pozzi S, Bari A, Ilariucci F, Stelitano C, Angrilli F, Lazzaro A, Baldini L.

Cancer. 2009 May 1;115(9):1906-13. doi: 10.1002/cncr.24222.

16.

BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.

van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA.

J Clin Oncol. 2010 May 1;28(13):2246-52. doi: 10.1200/JCO.2009.25.0852. Epub 2010 Apr 5.

PMID:
20368567
17.

ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.

van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, Löwenberg B, Sonneveld P.

Clin Pharmacol Ther. 2006 Nov;80(5):427-39.

PMID:
17112800
18.

[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].

Lü SQ, Yang JM, Song XM, Chen L, Zhang WP, Ni X, Xu XQ, Wang JM.

Zhonghua Zhong Liu Za Zhi. 2007 Sep;29(9):710-2. Chinese.

PMID:
18246806
19.

Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.

Tsutsumi Y, Kanamori H, Minami H, Musashi M, Fukushima A, Ehira N, Yamato H, Obara S, Ogura N, Tanaka J, Asaka M, Imamura M, Masauzi N.

Ann Hematol. 2005 Apr;84(4):269-71. Epub 2004 Nov 26.

PMID:
15592832
20.

Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.

Månsson E, Spasokoukotskaja T, Sällström J, Eriksson S, Albertioni F.

Cancer Res. 1999 Dec 1;59(23):5956-63.

Supplemental Content

Support Center